The company earlier announced that the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase IIb ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Shares of GH Research PLC (NASDAQ:GHRS) surged 90% following the announcement that its Phase 2b trial for GH001, an inhalable treatment for treatment-resistant depression (TRD), met its primary ...

DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...